Montis Biosciences Alternatives & Competitors
12 companies similar to Montis Biosciences — Pioneering next-gen therapeutics to harness C1q's central role in neuroinflammat...
Replicate Bioscience, Inc.
The Power of RNA Amplified
San Diego, United States
GlycoEra AG
Advancing Glycan Mediated Therapy
Wadenswil, Switzerland
Allogene Therapeutics
A biotechnology company catalyzing cancer treatment through the development of CAR T thera...
South San Francisco, Unit...
Orbital Therapeutics
Expanding RNA medicines to more tissues, more diseases, and more patients.
Cambridge, United States
Track all Montis Biosciences competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Prevail Therapeutics
Wholly owned subsidiary of Eli Lilly and Company
New York, United States
Libra Therapeutics
Restoring Cellular Balance: Developing novel therapeutics for neurodegenerative disease
San Diego, United States
EpiBiologics
Next Generation Protein Degradation
San Mateo, United States
Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics company discovering and developing t...
Singapore, Singapore
SanegeneBio
Sanegene Bio is committed to advancing transformative RNAi therapies that address global...
Woburn, United States
ROME Therapeutics
Harnessing the power of the repeatome to develop a new class of therapies for cancer and a...
Boston, United States
Georgiamune Inc.
Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...
Gaithersburg, United Stat...
Vertero Therapeutics, Inc.
Pioneering science beyond the brain to treat neurodegenerative diseases at their source
Woburn, United States
About Montis Biosciences
Pioneering next-gen therapeutics to harness C1q's central role in neuroinflammatory diseases.
Development of dual-mechanism antibodies, Research and development of therapeutics for neuroinflammatory diseases, Drug discovery in autoimmune and neurodegenerative diseases
Patients with autoimmune neuropathies, Patients with neurodegenerative disorders, Healthcare providers, Biopharmaceutical partners
Next-gen Therapeutics, Neuroinflammatory Diseases, Autoimmune Disorders, Neurodegenerative Diseases, C1q Modulation, Antibody Development, Complement Pathway, Classical Complement Cascade, CD93 Inhibition, Lung Squamous Cell Carcinoma, Phase 1 Clinical Trials, Inflammation-driven Oncology, Patient-centric Discovery, Drug Development Partnerships, Investor-backed Biotech
B2B
Licensing, Performance Based, Project Based
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Montis Biosciences and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Montis Biosciences on 15 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.